Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2023

17-03-2023 | Invited Commentary

Wrought Iron Thresholds: How Magnetic Resonance Liver Iron Concentration Can Guide Decision-Making in Hyperferritinemic Patients

Authors: Christopher Cussen, Aftab Ala

Published in: Digestive Diseases and Sciences | Issue 6/2023

Login to get access

Excerpt

Hemochromatosis is a common genetic cause of iron overload, most prevalent among people of Northern European ancestry, associated in > 80% of cases with homozygosity for the p.C282Y missense mutation on the High Fe++ (HFE) gene [1]. Though HFE p.C282Y:p.H63D and p.H63D:p.H63D mutations contribute to hyperferritinemia, they rarely cause clinically significant iron overload in the absence of additional risk factors [2]. Although elevated serum ferritin is a sensitive biomarker for diagnosing hemochromatosis and iron overload, its specificity is low. Though risk factors, including other hepatopathies, metabolic syndrome, systemic inflammation, and excessive alcohol intake can confound the serum ferritin, hyperferritinemia is also present in a wide variety of other diseases. This lack of specificity due to a spurious elevation of serum ferritin may complicate the diagnosis of iron overload and its treatment with venesection. Despite a low risk of hemochromatosis-related morbidity and the unclear benefits of venesection, 14–30% of venesection referrals are for compound heterozygotes [3], an observation not enhanced by the scarcity of clinical trials specifically investigating management of these genetic mutations. The EASL guidelines published in 2022 recommend further investigation for iron overload and management according to phenotypic presentation, leaving considerable scope for clinical judgement [1]. …
Literature
1.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Haemochromatosis. J Hepatol 2022;77:479–502.CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Haemochromatosis. J Hepatol 2022;77:479–502.CrossRef
2.
go back to reference Gurrin LC, Bertalli NA, Dalton GW et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94–101.CrossRefPubMed Gurrin LC, Bertalli NA, Dalton GW et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94–101.CrossRefPubMed
3.
go back to reference Bentley P, Bell B, Olynyk J. Therapeutic venesection at the Australian Red Cross Blood Service: impact of the High Ferritin Application on management of hereditary haemochromatosis. Aust Fam Physician 2015;44:589–592.PubMed Bentley P, Bell B, Olynyk J. Therapeutic venesection at the Australian Red Cross Blood Service: impact of the High Ferritin Application on management of hereditary haemochromatosis. Aust Fam Physician 2015;44:589–592.PubMed
4.
go back to reference Angelucci E, Brittenham G, McLaren C et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327–331.CrossRefPubMed Angelucci E, Brittenham G, McLaren C et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327–331.CrossRefPubMed
5.
go back to reference Akpinar S, Yilmaz G, Bulakbasi N et al. The role of diffusion-weighted imaging in prediction liver iron concentration in beta-thalassaemia patients. J Med Imaging Radiat Oncol 2018;62:169–173.CrossRefPubMed Akpinar S, Yilmaz G, Bulakbasi N et al. The role of diffusion-weighted imaging in prediction liver iron concentration in beta-thalassaemia patients. J Med Imaging Radiat Oncol 2018;62:169–173.CrossRefPubMed
6.
go back to reference Varghese A, Kelly L, Holmes H. Evaluating the Cost of Illness of Genetic Haemochromatosis in the UK. Haemochromatosis UK and York Health Economics Consortium, 2022. Varghese A, Kelly L, Holmes H. Evaluating the Cost of Illness of Genetic Haemochromatosis in the UK. Haemochromatosis UK and York Health Economics Consortium, 2022.
8.
go back to reference Jensen P, Jensen F, Christensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632–4639.CrossRefPubMed Jensen P, Jensen F, Christensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632–4639.CrossRefPubMed
Metadata
Title
Wrought Iron Thresholds: How Magnetic Resonance Liver Iron Concentration Can Guide Decision-Making in Hyperferritinemic Patients
Authors
Christopher Cussen
Aftab Ala
Publication date
17-03-2023
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2023
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-023-07880-x

Other articles of this Issue 6/2023

Digestive Diseases and Sciences 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.